Research Article

Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole's Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture

Volume: 18 Number: 1 June 30, 2025
EN TR

Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole's Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture

Abstract

Cancer is known as a major health problem globally. Breast cancer is the most common malignant tumor and metastasis continues to be the main cause of poor prognosis. Despite recent advances in cancer treatment, the success of metastatic breast cancer treatment is not at the desired level. Among the anticancer drugs discovered in recent years, various benzimidazole derivatives have attracted attention in the development of anticancer agents due to their various biological activities and clinical applications. The aim of this study was to evaluate the antiproliferative activity of synthesized benzimidazole derivative SA-61 in 4T1 breast cancer cell line in comparison with abemaciclib, which is approved by FDA for the treatment of breast cancer. The antiproliferative activity and apoptotic effect of SA-61 were examined using MTT and immunohistochemical methods, respectively. According to MTT results, compound SA-61 showed antiproliferative activity in 4T1 cells in a dose-dependent manner, but this effect was lower than abemaciclib. Although further studies are needed to specifically identify the compounds involved in its anti-cancer activity, our findings suggest that SA-61 inhibits the proliferation of 4T1 cells and its effect is dose dependent.

Keywords

References

  1. Choi HS, Ko YS, Jin H, et al. (2022). Mebendazole increases anticancer activity of radiotherapy in radiotherapy-resistant triple-negative breast cancer cells by enhancing natural killer ccell-mediated cytotoxicity. Int J Mol Sci. 7;23(24):15493.
  2. Medeiros B, Allan AL (2019). Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int. J. Mol. Sci. 20:2272.
  3. Pulaski BA, Ostrand-Rosenberg S (2001). Mouse 4T1 breast tumor model. Curr. Protoc Immunol. 39:20.2.1–20.2.16.
  4. Wagenblast E, Soto M, Gutiérrez-Ángel S, et al. (2015). A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 520:358–362.
  5. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 13:674–690.
  6. Lee YT, Tan YJ, Oon CE (2023). Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. Acta Pharm Sin B. 13(2):478-497.
  7. Hagar FF, Abbas SH, Atef E, Abdelhamid D, Abdel-Aziz M (2025). Benzimidazole scaffold as a potent anticancer agent with different mechanisms of action (2016-2023). Mol Divers. 29(2):1821-1849.
  8. Liu Y (2021). Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways. Fundam Clin Pharmacol. 35(1):156–64.

Details

Primary Language

English

Subjects

Veterinary Sciences (Other)

Journal Section

Research Article

Publication Date

June 30, 2025

Submission Date

March 26, 2025

Acceptance Date

May 20, 2025

Published in Issue

Year 2025 Volume: 18 Number: 1

APA
Bilici, E., Gülbenli Türkoğlu, B., & Akkoç, S. (2025). Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniversitesi Veteriner Fakültesi Dergisi, 18(1), 33-37. https://doi.org/10.47027/duvetfd.1666352
AMA
1.Bilici E, Gülbenli Türkoğlu B, Akkoç S. Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniv Vet Fak Derg. 2025;18(1):33-37. doi:10.47027/duvetfd.1666352
Chicago
Bilici, Esra, Büşra Gülbenli Türkoğlu, and Senem Akkoç. 2025. “Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture”. Dicle Üniversitesi Veteriner Fakültesi Dergisi 18 (1): 33-37. https://doi.org/10.47027/duvetfd.1666352.
EndNote
Bilici E, Gülbenli Türkoğlu B, Akkoç S (June 1, 2025) Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniversitesi Veteriner Fakültesi Dergisi 18 1 33–37.
IEEE
[1]E. Bilici, B. Gülbenli Türkoğlu, and S. Akkoç, “Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture”, Dicle Üniv Vet Fak Derg, vol. 18, no. 1, pp. 33–37, June 2025, doi: 10.47027/duvetfd.1666352.
ISNAD
Bilici, Esra - Gülbenli Türkoğlu, Büşra - Akkoç, Senem. “Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture”. Dicle Üniversitesi Veteriner Fakültesi Dergisi 18/1 (June 1, 2025): 33-37. https://doi.org/10.47027/duvetfd.1666352.
JAMA
1.Bilici E, Gülbenli Türkoğlu B, Akkoç S. Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniv Vet Fak Derg. 2025;18:33–37.
MLA
Bilici, Esra, et al. “Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture”. Dicle Üniversitesi Veteriner Fakültesi Dergisi, vol. 18, no. 1, June 2025, pp. 33-37, doi:10.47027/duvetfd.1666352.
Vancouver
1.Esra Bilici, Büşra Gülbenli Türkoğlu, Senem Akkoç. Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniv Vet Fak Derg. 2025 Jun. 1;18(1):33-7. doi:10.47027/duvetfd.1666352